Condition: Gastric Cancer · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal metastasis from gastric cancer. Furthermore, it seeks to analyze the effects of this treatment strategy on overall survival (OS), progression-free survival (PFS), PCI and adverse reaction rates.
This description comes directly from the study's public registry record.
Kaixiong Tao, PhD · 13507155452 · taokaixiong@hust.edu.cn
Yuping Yin, PhD · 15927412321 · yinyuping2017@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Wuhan Union Hospital | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06685887